For Q1 2025, Danaher said it expects core revenues will decline in the low-single digit percent range year over year. For full-year 2025, the company anticipates core revenues will increase ...

Life Sciences revenues rose 3 percent year over year to $7.33 billion from $7.14 billion. Diagnostic revenues increased 2 percent to $9.79 billion from $9.58 billion, while Biotechnology revenues ...

Life Sciences revenues rose 3 percent year over year to $7.33 billion from $7.14 billion. Diagnostic revenues increased 2 percent to $9.79 billion from $9.58 billion, while Biotechnology revenues ...

The test, which is intended for assessing cardiovascular risk, is the first lipoprotein (a), or Lp(a) test measured in nanomoles per liter to receive FDA clearance.

The €4.5 million ($4.2 million) effort is led by researchers from Sweden's Karolinska Institute and aims to deliver lateral flow tests and point-of-care devices.

The clinical chemistry test is intended to help diagnose heart failure using the N-terminal pro b-type natriuretic peptide biomarker.

Last week, readers were most interested in a story about Roche gaining FDA clearance and CLIA waiver for its STI point-of-care test.

The finalized local coverage determinations were set to go into effect on Feb. 23 but have been pushed back two months.

OraSure Technologies CEO Carrie Eglinton Manner said in her presentation that the firm's recent $25 million acquisition of ...

The molecular test is used to differentiate bacterial infections, viral infections, and noninfectious disease and to assess ...

Highlights from the first day included updates from several firms about their China businesses and M&A strategies.

Highlights from the third day included information about Quanterix's new Simoa One platform, expected to launch at the end of ...